Private: Gallery Post #1

10

Apr2015

Updates to the Manufacturer Submission Requirements in the Alberta Drug Benefit List (ADBL)

Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca For more information, please see ... Read More

07

Apr2015

CADTH: Guidelines for Manufacturers on pCODR Application Fees Implemented

CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month. Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation. For ... Read More

30

Mar2015

Rare Diseases Campaign

We recently participated in Mediaplanet Canada’s Rare Diseases campaign in which many industry leaders united to provide Canadians with a comprehensive view of Canada’s healthcare system and the policies that affect the lives of those living with or affected by rare disorders. The campaign was distributed through the National Post on ... Read More

25

Mar2015

The pan-Canadian Oncology Drug Review (pCODR) is moving

Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto. Please note the new main telephone and fax ... Read More

12

Mar2015

CADTH Revised Category 1 Requirements for Tailored CDR Reviews

Category 1 requirements for products that undergo a tailored CDR review have been revised. Submissions for new combination products (funded components) and new combination products designated by CADTH to undergo a tailored CDR review will require completion of the revised New Combination Product Submission Template.  This revised template ... Read More

05

Mar2015

Guidelines for Manufacturers on Application Fees for pCODR

CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More

23

Feb2015

Pan-Canadian Generics – Centralized Price Confirmation Process

Effective February 9, 2015 and until this process is transitioned to the pan-Canadian Pharmaceutical Alliance (pCPA) office, Saskatchewan will serve as the single point of entry for the pan-Canadian generic price tier confirmation process. The Saskatchewan Drug Plan will verify that the Tiered Pricing Framework applies to the ... Read More

04

Feb2015

CADTH Update for Patient Groups — January 2015

Pilot Extension for Individual Patient Input to the Common Drug Review The Common Drug Review (CDR) is extending its pilot to receive patient input submissions from individual patients and caregivers until August 3, 2015. Pilot Extension for Patient Input for Therapeutic Reviews CADTH implemented a pilot process for receiving patient input submissions for ... Read More

04

Feb2015

PMPRB Update – January 2015 NEWSletter

PMPRB The PMPRB has released its January 2015 NEWSletter Topics covered in the NEWSletter include: Final 2014 CPI-Based Price-Adjustment Factors: The final CPI figures for 2014 are now available. Of note: The actual CPI-based price-adjustment factor for 2 year (2012) and 3 year (2011) are lower than forecast. As a result, some manufacturers/patentees may ... Read More

14

Jan2015

Drug products undergoing evaluation for the June 2015 “Liste des médicaments”

QUEBEC L’Institut national d’excellence en santé et en services sociaux (INESSS) has released the list of drug products submitted for the June 2015 “Liste des médicaments.” Health professionals, citizens and patients and their associations and groups have until ... Read More